SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 26, 2013--
Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey,
Ph.D., the company’s president and chief executive officer, will present
at the 25th Annual Piper Jaffray Healthcare Conference at
10:30 a.m. EST/7:30 a.m. PST on Tuesday, December 3, 2013 in New York.
During the presentation, Dr. Morrissey will review the company’s
development plans and priorities for cabozantinib. He will also discuss
the company’s corporate strategy and financial outlook, and provide a
general business update.
The presentation will be webcast and may be accessed via the Event
Calendar page under Investors & Media at www.exelixis.com.
About Exelixis
Exelixis, Inc. is a biotechnology company committed to developing small
molecule therapies for the treatment of cancer. Exelixis is focusing its
proprietary resources and development efforts exclusively on COMETRIQ®
(cabozantinib). Exelixis has also established a portfolio of other novel
compounds that it believes have the potential to address serious unmet
medical needs, many of which are being advanced by partners as part of
collaborations. For more information, please visit the company's web
site at www.exelixis.com.
Exelixis, the Exelixis logo, and COMETRIQ are registered U.S.
trademarks.
Source: Exelixis, Inc.
Exelixis, Inc.
Charles Butler, 650-837-7277
Vice President,
Investor Relations and Corporate Communications
cbutler@exelixis.com
